These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

647 related articles for article (PubMed ID: 31997805)

  • 21. Ketogenic Diet in Alzheimer's Disease.
    Rusek M; Pluta R; Ułamek-Kozioł M; Czuczwar SJ
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31405021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics.
    Butterfield DA; Perluigi M; Sultana R
    Eur J Pharmacol; 2006 Sep; 545(1):39-50. PubMed ID: 16860790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
    Clausen A; Xu X; Bi X; Baudry M
    J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Alzheimer's disease: lesions and their progression].
    Duyckaerts C; Colle MA; Delatour B; Hauw JJ
    Rev Neurol (Paris); 1999; 155 Suppl 4():S17-27. PubMed ID: 10637934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The complex effects of miR-146a in the pathogenesis of Alzheimer's disease.
    Long Y; Liu J; Wang Y; Guo H; Cui G
    Neural Regen Res; 2025 May; 20(5):1309-1323. PubMed ID: 39075895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDG-PET and amyloid-PET imaging: the diverging paths.
    Perani D
    Curr Opin Neurol; 2014 Aug; 27(4):405-13. PubMed ID: 24927239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Autophagy for the Treatment of Alzheimer's Disease: Challenges and Opportunities.
    Liu J; Li L
    Front Mol Neurosci; 2019; 12():203. PubMed ID: 31507373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer's disease: as it was in the beginning.
    Kozlov S; Afonin A; Evsyukov I; Bondarenko A
    Rev Neurosci; 2017 Nov; 28(8):825-843. PubMed ID: 28704198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Alzheimer's amyloid-beta and tau protein on mitochondrial function -- role of glucose metabolism and insulin signalling.
    Rhein V; Eckert A
    Arch Physiol Biochem; 2007 Jun; 113(3):131-41. PubMed ID: 17922309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease.
    Jazvinšćak Jembrek M; Slade N; Hof PR; Šimić G
    Prog Neurobiol; 2018 Sep; 168():104-127. PubMed ID: 29733887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
    Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
    Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Alzheimer's disease: new prospects in therapy and applied experimental models].
    Kubis AM; Janusz M
    Postepy Hig Med Dosw (Online); 2008 Aug; 62():372-92. PubMed ID: 18688208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Review on Tau Targeting Biomimetics Nano Formulations: Novel Approach for Targeting Alzheimer's Diseases.
    Singh A; Maheshwari S; Yadav JP; Varshney AP; Singh S; Prajapati BG
    Cent Nerv Syst Agents Med Chem; 2024; 24(3):294-303. PubMed ID: 38646682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease.
    Jacobsen JS; Reinhart P; Pangalos MN
    NeuroRx; 2005 Oct; 2(4):612-26. PubMed ID: 16489369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Streptozotocin Intracerebroventricular-Induced Neurotoxicity and Brain Insulin Resistance: a Therapeutic Intervention for Treatment of Sporadic Alzheimer's Disease (sAD)-Like Pathology.
    Kamat PK; Kalani A; Rai S; Tota SK; Kumar A; Ahmad AS
    Mol Neurobiol; 2016 Sep; 53(7):4548-62. PubMed ID: 26298663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitochondrial dysfunction in sporadic and genetic Alzheimer's disease.
    Hauptmann S; Keil U; Scherping I; Bonert A; Eckert A; Müller WE
    Exp Gerontol; 2006 Jul; 41(7):668-73. PubMed ID: 16677790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarkers, ketone bodies, and the prevention of Alzheimer's disease.
    VanItallie TB
    Metabolism; 2015 Mar; 64(3 Suppl 1):S51-7. PubMed ID: 25468143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
    Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
    Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.